Minimally invasive artery embolization for chronic Achilles tendon pain
Official title: Achilles Tendinopathy Embolization (ATE) With LipioJoint: An Early Feasibility Study
Run by Joint & Vascular Institute · NCT07477860 · Data updated 2026-11-12
This trial will try injecting a temporary Lipiodol emulsion into blood vessels feeding the Achilles tendon to reduce chronic tendon pain in adults 25 to 80 who haven't improved after conservative treatment.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 25 Years to 80 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Joint & Vascular Institute Industry-sponsored |
| Locations | 1 site (Libertyville, Illinois) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT07477860 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 25–80 with chronic Achilles tendinopathy resistant to at least three months of conservative care, reporting at least 4/10 pain on the VAS and who prefer to avoid surgery are the intended participants.
✕Probably not a fit
People with acute fracture/trauma, inflammatory tendon disease, recent steroid injection (within 90 days), peripheral arterial disease, severe contrast allergy, impaired kidney function (GFR <45 or creatinine >2.0 mg/dL), type 1 diabetes, pregnancy/breastfeeding, anticoagulation or irreversible coagulopathy, or tendon rupture are excluded and unlikely to benefit from this procedure.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants undergo a minimally invasive catheter procedure in which a radiologist injects a temporary blocking agent (LipioJoint/Lipiodol emulsion) into specific arteries supplying the affected Achilles tendon. Pain intensity will be measured using the Visual Analog Scale (VAS) at baseline and at 1, 3, 6, and 12 months after the procedure, with a phone check one day after treatment to screen for early side effects. The study is a Phase 1 interventional trial focused on feasibility and safety, tracking serious adverse events related to the device and procedure over 12 months. The goal is to determine whether the procedure can safely and durably reduce chronic Achilles pain in adults who are non-surgical candidates or wish to avoid surgery.
Why it matters
Potential benefit: If successful, this procedure could reduce chronic Achilles tendon pain and offer a less invasive alternative to surgery.
How similar studies have gone: Early case series and small observational studies of arterial embolization for tendinopathies have reported promising pain reductions, but larger controlled trials are still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 25 years * Subject provides written informed consent * Patient with Achilles tendinopathy refractory to 3 months of conservative management * Self reported pain of at least 4/10 on visual analog scale (VAS) * Non-surgical candidate/looking to avoid surgery Exclusion Criteria: * Achilles tendon pain caused by acute fracture, recent trauma, inflammatory conditions, muscle/ligament injury, tendon rupture, and etiologies related to bone mineral density * Steroid injection in the last 90 days from the embolization procedure * Known severe allergy to Lipiodol and/or iodinated contrast media * Diagnosis of peripheral arterial disease affecting the lower extremities * Pregnancy or breastfeeding * Anticoagulation or irreversible coagulopathy * GFR \<45 or Serum creatinine \> 2.0 mg/dl * Type 1 Diabetes Mellitus
Where it's running
-
Joint and Vascular Institute
Libertyville, Illinois, United States Recruiting
Study contacts
- Study coordinator: Layth Alkhani
- Email: lalkhani@jointvascular.com
- Phone: 847-584-3959
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Corticosteroid injections added to standard care for chronic midportion Achilles tendinopathy
This trial tests whether 1–3 ultrasound-guided corticosteroid injections added to standard care help adults with long-standing midportion Achilles tendinopathy more than placebo injections plus standard care.
-
Foot position during Achilles tendinopathy rehab
This trial tests whether doing a 12-week load-based exercise with a toes-out foot position helps the Achilles better heal and function compared with a neutral foot position in adults with mid-portion Achilles tendinopathy.
-
Platelet-rich plasma treatment for patellar, Achilles, elbow (epicondylitis), and plantar heel tendinopathies.
This multicenter observational project will try platelet-rich plasma (PRP) injections to see if they reduce pain and improve function in adults with chronic patellar, Achilles, lateral elbow (epicondylitis), or plantar heel (fasciitis) tendinopathies.
-
ATOR screening scores over 12 weeks in senior runners with Achilles tendinopathy
We will test whether adding analytical stretching to an Alfredson exercise program plus health education improves ATOR screening scores over 12 weeks in senior club runners with Achilles tendinopathy.
-
Immediate neuromuscular electrical stimulation for Achilles tendon pain and function
Researchers will try two types of neuromuscular electrical stimulation to see if they immediately reduce pain and improve heel-rise performance in people with Achilles tendinopathy or a past Achilles tendon rupture.
-
Hyaluronic Acid vs Platelet-R-rich Plasma for Chronic Tendinopathy and Enthesopathy
This study tests whether injections of hyaluronic acid or autologous platelet-rich plasma can help people with chronic tendon and enthesis problems in the elbow or Achilles area.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.